S102
Brachytherapy - Head & neck, skin, eye
ESTRO 2026
treatment option for selected patients with non- melanoma skin cancer. It provides high local control rates with minimal toxicity, representing an excellent alternative for patients who are not candidates for surgery or when preservation of function and appearance is a priority. Keywords: Cosmetic, Non-melanoma skin,
Oncology Institute of Porto Oncology Institute of Porto, Porto, Portugal
Purpose/Objective: Non-melanoma skin cancer (NMSC) is the most frequent skin malignancy and may cause significant cosmetic and functional morbidity when treated surgically. High-dose-rate (HDR) plesiotherapy represents a precise and effective alternative for the treatment of superficial lesions, particularly in patients unsuitable for surgery. Recent evidence supports the efficacy of tailored skin brachytherapy, offering excellent local control, low toxicity, and favorable cosmetic results with a wide range of dose schedules adaptable to patient needs.This study aimed to evaluate clinical outcomes, toxicity, and cosmetic results in patients with NMSC treated with HDR plesiotherapy. Material/Methods: Between december 2012 and december 2023, 16 patients (17 lesions) with histologically confirmed NMSC were treated with HDR plesiotherapy using tubes, or catheters, embedded into the customized moulds at specific, parallel distances. The total prescribed dose ranged from 32 Gy to 40 Gy, delivered in 10 fractions twice weekly over 4 weeks. Patient and tumour characteristics, treatment parameters, clinical outcomes, acute and late toxicity, and cosmetic results were retrospectively analyzed. Toxicity was graded according to RTOG criteria, and cosmetic outcomes were clinically assessed at follow-up. Results: After a median follow-up of 33 months (range: 4–90), the median patient age was 68 years (range: 53–90). Lesions were mainly located on the scalp and face, with basal cell carcinoma being the most frequent histology (56%), followed by squamous cell carcinoma (31%), angiosarcoma (6%), and sebaceous carcinoma (6%).The median total dose was 40 Gy (range: 32–50 Gy) in 10 fractions. Acute toxicity occurred in 81% of cases, predominantly Grade I–II radiodermitis, while two patients developed Grade III reactions. Late toxicity was observed in three patients (19%), including hyperpigmentation, telangiectasia, and skin atrophy.Cosmetic outcome was rated as good or excellent in 50% of cases. At the last follow-up, complete response was achieved in 94% of lesions, while one case (6%) showed partial response. Two local recurrences were documented—one following partial response and another after complete remission. The 5-year disease-free survival rate was 84%. Conclusion: The results of our study are consistent with those reported in the literature, concluding that HDR brachytherapy using custom-made molds is an effective, well-tolerated, and cosmetically favorable
Plesiotherapy References:
Guinot JL, Rembielak A, Perez-Calatayud J, Rodríguez- Villalba S, Skowronek J, Tagliaferri L, Guix B, Gonzalez- Perez V, Valentini V, Kovacs G; on behalf of the GEC- ESTRO. GEC-ESTRO ACROP recommendations in skin
brachytherapy. Radiotherapy and Oncology. 2018;126(3):377–385. doi:10.1016/j.radonc.2018.01.013
Mini-Oral 2866 Local failure after ruthenium-106 plaque brachytherapy for uveal melanoma is correlated to institutes’ annual treatment volume Lennart J Pors 1,2 , T. H. Khanh Vu 2 , Ellen M Kerkhof 1 , Coen R.N. Rasch 1,3 , Jan-Willem M Beenakker 2,4 1 Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands. 2 Department of Ophthalmology, Leiden University Medical Center, Leiden, Netherlands. 3 Holland Proton Therapy Center, Holland Proton Therapy Center, Delft, Netherlands. 4 Department of Radiology, Leiden University Medical Center, Leiden, Netherlands Purpose/Objective: Uveal melanoma (UM), the most prevalent ocular malignancy in adults, is often treated eye-sparingly using ruthenium-106 brachytherapy. Published local failure risks after this treatment, however, vary between 58-99%. We aimed to explore the cause of this variety by investigating the relation between a treating centers annual treatment volume (ATV) and the risk of local failure at five years after ruthenium- 106 brachytherapy for UM. Material/Methods: We performed a systematic review and meta-analysis using a random effects model of all studies with at least 10 UM patients treated with ruthenium-106 brachytherapy of which at least one was treated after 2000, with a median follow-up of at least 3 years, that reported the local failure risk. Title/abstract and full text screening were performed systematically by two independent observers (LJP and JWB), and conflicts were resolved in consensus meetings. Data extraction was performed by one and checked in a consensus meeting by both observers. The review was pre- registered under the PROSPERO ID CRD420251030957.
Made with FlippingBook - Share PDF online